Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vesicare, VesiCare LS
Solifenacin is a competitive muscarinic receptor antagonist used to treat overactive bladder (OAB). It belongs to a class of drugs called urinary antispasmodics and primarily targets the M3 muscarinic receptor subtype in the bladder, reducing involuntary bladder contractions and thus decreasing the urge to urinate frequently.
Solifenacin is used to treat symptoms of overactive bladder, such as frequent urination, urgency, and urge incontinence.
Outcome:
Increased solifenacin levels
Mechanism:
Ketoconazole inhibits CYP3A4, the primary enzyme metabolizing solifenacin.
Outcome:
Potential for altered warfarin effects
Mechanism:
Solifenacin may affect warfarin metabolism.
Outcome:
Slightly decreased solifenacin absorption
Mechanism:
Antacids can affect drug absorption.
Most likely new formulation: Extended-release formulation with improved tolerability (Year 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a low ( <5%) likelihood of significant regulatory changes to solifenacin's labeling in the next 2 years.
Urinary Antispasmodic, Muscarinic Antagonist
Quinuclidine derivative